Accueil >
Publications >
Sex, gender, and retinoblastoma: analysis of 4351 patients from 153 countries

Sex, gender, and retinoblastoma: analysis of 4351 patients from 153 countries

1 août 2022Eye

Auteurs

Ido Didi Fabian, Vikas Khetan, Andrew W. Stacey, Allen Foster, Dupe S. Ademola-Popoola, Jesse L. Berry, Nathalie Cassoux, Guillermo L. Chantada, Laila Hessissen, Swathi Kaliki, Tero T. Kivelä, Sandra Luna-Fineman, Francis L. Munier, M. Ashwin Reddy, Duangnate Rojanaporn, Sharon Blum, Sadik T. Sherief, Sandra E. Staffieri, Tuyisabe Theophile, Keith Waddell, Xunda Ji, Nicholas J. Astbury, Covadonga Bascaran, Matthew Burton, Marcia Zondervan, Richard Bowman,

Résumé

Abstract

Objective

To investigate in a large global sample of patients with retinoblastoma whether sex predilection exists for this childhood eye cancer.

Methods

A cross-sectional analysis including 4351 treatment-naive retinoblastoma patients from 153 countries who presented to 278 treatment centers across the world in 2017. The sex ratio (male/female) in the sample was compared to the sex ratio at birth by means of a two-sided proportions test at global level, country economic grouping, continent, and for selected countries.

Results

For the entire sample, the mean retinoblastoma sex ratio, 1.20, was higher than the weighted global sex ratio at birth, 1.07 (p < 0.001). Analysis at economic grouping, continent, and country-level demonstrated differences in the sex ratio in the sample compared to the ratio at birth in lower-middle-income countries (n = 1940), 1.23 vs. 1.07 (p = 0.019); Asia (n = 2276), 1.28 vs. 1.06 (p < 0.001); and India (n = 558), 1.52 vs. 1.11 (p = 0.008). Sensitivity analysis, excluding data from India, showed that differences remained significant for the remaining sample (χ2 = 6.925, corrected p = 0.025) and for Asia (χ2 = 5.084, corrected p = 0.036). Excluding data from Asia, differences for the remaining sample were nonsignificant (χ2 = 2.205, p = 0.14).

Conclusions

No proof of sex predilection in retinoblastoma was found in the present study, which is estimated to include over half of new retinoblastoma patients worldwide in 2017. A high male to female ratio in Asian countries, India in specific, which may have had an impact on global-level analysis, is likely due to gender discrimination in access to care in these countries, rather than a biological difference between sexes.